Tirzepatide is a GIP-sequence-based acylated peptide that selectively activates the GIP and GLP-1 receptors, with greater GIP-receptor engagement and distinct GLP-1-receptor signaling observed in mechanistic studies. FDA has approved tirzepatide in the finished drugs Mounjaro and Zepbound for specific labeled uses. Apex Laboratory supplies Tirzepatide as a research-grade chemical reagent for in-vitro and preclinical research, distinct from the Mounjaro and Zepbound pharmaceutical formulations.
Tirzepatide is often compressed into a slogan such as “dual incretin.” That description is directionally correct but incomplete. The molecule has a defined GIP-sequence-based design, unequal engagement of its two receptors, a distinctive GLP-1-receptor signaling profile, multiple clinical evidence programs, and two separate U.S. finished-drug applications. Those layers should be connected without being collapsed.
This page owns Tirzepatide identity, dual GIPR/GLP-1R pharmacology, representative SURPASS and SURMOUNT evidence, and the boundary between an Apex research reagent and the approved Mounjaro and Zepbound finished drugs. Pairwise comparison intent belongs to the dedicated Retatrutide versus Tirzepatide and Semaglutide versus Tirzepatide pages.
- Tirzepatide is a modified GIP-sequence-based peptide with a C20 fatty-diacid component and activity at GIPR and GLP-1R.
- Mechanistic studies describe greater GIPR engagement and GLP-1R signaling biased toward cAMP over beta-arrestin recruitment.
- SURPASS and SURMOUNT answer different clinical questions and do not establish the properties of a separate research lot.
- Mounjaro and Zepbound are distinct FDA-approved finished drugs under separate NDAs, despite sharing tirzepatide as the active molecule.
- Same molecule (tirzepatide); categorically distinct regulatory frameworks.
- A Certificate of Analysis can support lot-specific analytical questions, not clinical or regulatory equivalence.
What Is Tirzepatide?
Tirzepatide, originally designated LY3298176, is a synthetic acylated peptide derived from the GIP sequence and engineered to activate the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). The discovery publication connected receptor activity in recombinant and native systems with glucose and body-weight observations in mice and in early human research. In its 4-week Phase 1b proof-of-concept stage in adults with type 2 diabetes, LY3298176 10 mg and 15 mg lowered fasting serum glucose by a least-squares mean of 49.12 and 43.15 mg/dL against placebo, and 142 human subjects received at least one dose across the Phase 1 program.[1]
The current FDA description provides a precise identity layer. Tirzepatide is based on the GIP sequence, includes aminoisobutyric acid at positions 2 and 13, has a C-terminal amide, and carries a linker from the lysine at position 20 to a C20 fatty diacid. The fatty-diacid component supports albumin binding. These features help distinguish Tirzepatide from native GIP, native GLP-1, selective GLP-1-receptor agonists, and triple-receptor candidates.
| Identity attribute | Value | Source |
|---|---|---|
| CAS Registry Number | 2023788-19-2 | CAS registry, free base |
| Empirical formula | C225H348N48O68 | FDA Mounjaro label §11 |
| Molecular weight | 4813.53 Da | FDA Mounjaro label §11 |
| Sequence | 39 residues, GIP backbone: YXEGTFTSDY SIXLDKIAQK AFVQWLIAGG PSSGAPPPS (X = aminoisobutyric acid, positions 2 and 13); C-terminal amide | FDA Mounjaro label §11 |
| Acylation | Lys20 to 1,20-eicosanedioic acid (C20 fatty diacid) via a linker | FDA Mounjaro label §11 |
“Tirzepatide” can identify the active molecule while leaving the material context unresolved. A research reagent, a sponsor’s investigational material, Mounjaro, and Zepbound may share active-molecule identity without sharing excipients, manufacturing controls, sterility, container closure, labeling, intended use, or evidence ownership.
Exposure profile and protocol dose ranges
The C20 fatty diacid is what makes a weekly interval workable. FDA prescribing information reports 99% binding to plasma albumin, maximum plasma concentration 8 to 72 hours after subcutaneous administration, and an elimination half-life of approximately 5 days (about 120 hours) in humans. Approved single-dose presentations are 2.5, 5, 7.5, 10, 12.5, and 15 mg per 0.5 mL. SURPASS and SURMOUNT protocols started at 2.5 mg weekly and escalated by 2.5 mg every 4 weeks to maintenance doses of 5, 10, or 15 mg. These are finished-drug values, not attributes of a research lot.
How Does Tirzepatide’s Dual-Incretin Pharmacology Work?
GIPR and GLP-1R are distinct class B G-protein-coupled receptors activated by different native incretin hormones. Both can influence glucose-dependent insulin secretion, but their tissue distribution, signaling, trafficking, and physiological effects are not identical. Tirzepatide was engineered to engage both receptor systems in one molecule rather than combine two separate agents.
The FDA mechanism description states that Tirzepatide selectively binds to and activates GIPR and GLP-1R. In finished-drug studies, activation is associated with glucose-dependent insulin secretion and changes in glucagon signaling, appetite-related pathways, food intake, and gastric emptying. Those statements belong to the reviewed finished-drug evidence and should not be transformed into an activity guarantee for a research lot.
Mechanistic research provides more resolution. Tirzepatide behaved similarly to native GIP at GIPR in several signaling systems, while its GLP-1R behavior differed from native GLP-1. That difference is why “dual agonist” is a starting classification rather than a complete pharmacologic description.
What Do “Imbalanced” and “Biased” Mean for Tirzepatide?
“Imbalanced” refers to the relative engagement of the two receptors. Willard and colleagues estimated greater Tirzepatide engagement at GIPR than at GLP-1R under clinically relevant exposure modeling and receptor-occupancy assumptions. The paper did not describe two equal signals simply added together; it described a dual agonist with a GIPR-favoring balance.[2] That paper reports no quantitative endpoint; it is a receptor-occupancy and signaling characterization, not an effect size.
“Biased” refers to signaling pathways downstream of a receptor. At GLP-1R, Tirzepatide favored cyclic-AMP generation over beta-arrestin recruitment and produced less receptor internalization than native GLP-1 in the reported systems. At GIPR, its profile was closer to native GIP. Structural work using cryo-electron microscopy and molecular-dynamics analysis connected the sequence and fatty-acid modification to these receptor-specific interactions.[3] That structural report also states no quantitative endpoint; it resolves contact geometry, not magnitude of effect.
The limits are important. The mechanistic studies establish receptor and pathway behavior in defined systems. They do not prove that signaling bias alone causes the magnitude of every clinical result. They also do not show that any material labeled Tirzepatide has equivalent receptor activity. A biological-activity question requires a validated assay, appropriate controls, and a defined material.
What Do SURPASS and SURMOUNT Establish?
The clinical evidence is organized into programs with different populations and endpoints. SURPASS primarily evaluated type 2 diabetes questions. SURMOUNT primarily evaluated obesity, weight-maintenance, and related questions. SURMOUNT-OSA evaluated obstructive sleep apnea in adults with obesity. A program name is therefore a useful clue to evidence ownership, not a synonym for all Tirzepatide research.
Representative SURPASS evidence
SURPASS-1 was a 40-week, randomized, double-blind, placebo-controlled Phase 3 trial in 478 adults whose type 2 diabetes was inadequately controlled with diet and exercise. Mean glycated hemoglobin fell by 1.87, 1.89, and 2.07 percentage points on tirzepatide 5, 10, and 15 mg against a 0.04-point rise on placebo, and dose-dependent body-weight loss ranged from 7.0 to 9.5 kg. Gastrointestinal events were the most frequent adverse events.[4]
SURPASS-2 was an open-label, 40-week active-comparator Phase 3 trial in 1,879 adults with type 2 diabetes, randomized to tirzepatide 5, 10, or 15 mg or to semaglutide 1 mg once weekly. Mean glycated hemoglobin changed by −2.01, −2.24, and −2.30 percentage points across the tirzepatide doses and by −1.86 percentage points on the comparator.[5] Head-to-head interpretation belongs to the dedicated comparison page rather than to this entity guide. This page uses SURPASS-2 to place the evidence program, not to recommend one finished drug over another.
Representative SURMOUNT evidence
SURMOUNT-1 was a 72-week, double-blind, randomized, placebo-controlled Phase 3 trial in 2,539 adults with obesity or overweight plus a qualifying complication, excluding diabetes. Mean body-weight change at week 72 was −15.0%, −19.5%, and −20.9% on tirzepatide 5, 10, and 15 mg, against −3.1% on placebo; a reduction of 20% or more was reached by 50% and 57% of the 10 mg and 15 mg groups versus 3% on placebo. Gastrointestinal events were the most common adverse events, and discontinuations differed across groups.[6]
SURMOUNT-4 used a randomized-withdrawal design. After a 36-week open-label lead-in in which participants lost a mean 20.9% of body weight, 670 adults were randomized to continue tirzepatide or switch to placebo for 52 weeks. Mean body weight changed by −5.5% on continued tirzepatide and +14.0% on placebo between week 36 and week 88.[7] That design supports a maintenance question for the studied finished-drug context. It is not evidence for a research reagent and is not a personal-use instruction.
SURMOUNT-OSA and the OSA evidence lane
SURMOUNT-OSA comprised two randomized trials totaling 469 adults with moderate-to-severe obstructive sleep apnea and obesity, separated by baseline positive-airway-pressure use. At week 52 the mean apnea-hypopnea index fell by 25.3 versus 5.3 events per hour without baseline airway-pressure therapy, and by 29.3 versus 5.5 events per hour with it, and several prespecified secondary measures improved. Gastrointestinal events were again the most frequently reported adverse events.[8]
Those trials later supported a specific Zepbound indication. The regulatory conclusion belongs to the reviewed Zepbound application, studied population, formulation, and label. It does not turn every Tirzepatide material into an OSA drug.
Additional reported findings
The remaining registrational trials and the dedicated PK study, all in human adults, are recorded as readouts.
| Study | Population and design | Reported result | Source |
|---|---|---|---|
| SURPASS-3 | 1,437 adults, T2D on metformin ± SGLT2 inhibitor; open-label vs insulin degludec, 52 weeks | HbA1c −1.93/−2.20/−2.37 vs −1.34 points; weight −7.5 to −12.9 kg vs +2.3 kg | PMID 34370970 |
| SURPASS-4 | 1,995 adults, T2D with elevated cardiovascular risk; open-label vs insulin glargine, 52 weeks | HbA1c −2.43 (10 mg) and −2.58 (15 mg) vs −1.44 points; MACE-4 hazard ratio 0.74 (95% CI 0.51–1.08) | PMID 34672967 |
| SURPASS-5 | 475 adults, T2D on insulin glargine; placebo-controlled add-on, 40 weeks | HbA1c −2.11/−2.40/−2.34 vs −0.86 points; weight −5.4/−7.5/−8.8 kg vs +1.6 kg | PMID 35133415 |
| SURMOUNT-2 | 938 adults, obesity with T2D; placebo-controlled, 72 weeks | Weight −12.8% (10 mg) and −14.7% (15 mg) vs −3.2% | PMID 37385275 |
| SURMOUNT-3 | 579 adults, overweight or obesity after a 12-week lifestyle lead-in; placebo-controlled, 72 weeks | Additional weight −18.4% vs +2.5%; further loss ≥5% in 87.5% vs 16.5% | PMID 37840095 |
| Renal-impairment PK | 45 adults, five renal-function strata; single 5 mg subcutaneous dose | AUC and Cmax 90% CI spanned unity except 25–29% higher AUC under moderate impairment | PMID 33778934 |
| Evidence owner | Primary question | What should not be inferred |
|---|---|---|
| Discovery and mechanism studies | Identity, receptor activation, signaling, and trafficking | That one pathway explains every clinical outcome |
| SURPASS | Defined type 2 diabetes outcomes and safety observations | Obesity or OSA conclusions outside the relevant trials and labels |
| SURMOUNT | Defined obesity and maintenance outcomes | Glycemic, OSA, or research-lot equivalence claims |
| SURMOUNT-OSA | OSA outcomes in adults with obesity | A conclusion for people outside the studied population |
| FDA applications | Specific finished-drug formulations and labeled uses | Approval or clinical equivalence for an Apex research reagent |
What Is the Current FDA Status of Tirzepatide?
FDA first approved Mounjaro (tirzepatide), NDA 215866, on May 13, 2022. The original approval covered glycemic control in adults with type 2 diabetes. The current Mounjaro prescribing information, revised January 2026, covers adults and pediatric patients 10 years of age and older with type 2 diabetes. The original FDA approval letter remains the primary source for the first approval date.
FDA approved Zepbound (tirzepatide), NDA 217806, on November 8, 2023 for chronic weight management in specified adults. The Zepbound approval letter records the original action. FDA added an indication for moderate-to-severe obstructive sleep apnea in adults with obesity on December 20, 2024. The current Zepbound prescribing information, revised February 2026, contains both adult indications.
These are approvals of finished pharmaceutical formulations, not approvals of a free-standing molecular name for any intended use. FDA reviewed named sponsors, manufacturing information, container systems, formulations, evidence packages, labeling, and postmarketing obligations under two NDAs.
Why Are Mounjaro, Zepbound, and Apex Tirzepatide Categorically Different?
Same molecule (tirzepatide); categorically distinct regulatory frameworks. Mounjaro and Zepbound are FDA-approved finished pharmaceutical formulations under NDA 215866 and NDA 217806. Apex Tirzepatide is a chemical reagent for in-vitro and preclinical research, not for human consumption. Shared active-molecule identity does not transfer formulation, sterility, labeling, indication, clinical evidence, or therapeutic equivalence. The reagent itself holds no FDA, EMA, NMPA, MHRA, or other marketing authorization in any jurisdiction, and no Apex lot has been reviewed by any regulator for human use.
This distinction prevents two common errors. The first is to describe an analytical research lot with the attributes of a sterile finished drug. The second is to transfer clinical outcomes from a sponsor’s formulation to a material that was not studied in the trial. Neither transfer is justified by matching the expected peptide name or mass.
The broader research-grade versus pharmaceutical-grade guide explains why purity language is not a shortcut around formulation and regulatory differences. “High purity” is an analytical claim under a stated method; it is not a pharmaceutical-quality, sterility, or therapeutic-equivalence claim.
How Should Tirzepatide Evidence and Research Material Be Evaluated?
Begin by naming the material context. Is the source about the Tirzepatide molecule, a mechanistic construct, Mounjaro, Zepbound, or a specific research lot? Next identify the source level. FDA labeling owns current finished-drug indications. Randomized trials own outcomes in their studied populations. Mechanistic papers own receptor and pathway findings. Lot documents own only the analytical attributes they actually report.
For a research material, separate identity from purity and activity. Mass spectrometry can test whether observed ions support the expected analyte mass. HPLC can report chromatographic purity under a stated method and detection system. Neither method establishes GIPR or GLP-1R activity, sterility, clinical formulation, or equivalence to Mounjaro or Zepbound. The Apex guides to mass-spectrometry identity testing and HPLC purity interpretation provide the analytical framework.
Finally, preserve comparison ownership. A comparison page should define the comparator, endpoint, population, and source date. This entity page should not repeat a selective set of head-to-head numbers in a way that competes with or contradicts the dedicated comparison URLs. That separation improves internal linking and reduces intent cannibalization.
Frequently Asked Questions
What is Tirzepatide?
Tirzepatide is a GIP-sequence-based acylated peptide that selectively activates the GIP and GLP-1 receptors. It was originally identified by the development code LY3298176.
Why is Tirzepatide called a dual agonist?
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The relative engagement and downstream signaling are not identical at the two receptors.
What do imbalanced and biased mean for Tirzepatide?
Imbalanced refers to greater modeled engagement at GIPR than GLP-1R. Biased refers to Tirzepatide favoring cAMP signaling over beta-arrestin recruitment at GLP-1R in mechanistic studies.
Do Mounjaro and Zepbound contain the same active molecule?
Yes. Both contain tirzepatide, but they are separate FDA-approved finished-drug applications with different labeled scopes and regulatory records.
What is Mounjaro’s current FDA-labeled scope?
The January 2026 label covers glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes, as an adjunct to diet and exercise.
What is Zepbound’s current FDA-labeled scope?
The February 2026 label covers adult chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity, within the label’s stated conditions.
Is Apex Tirzepatide the same product as Mounjaro or Zepbound?
No. Apex Tirzepatide is a research-grade chemical reagent, not an FDA-approved finished drug, and it does not inherit either product’s formulation, labeling, sterility, trial evidence, or approved uses.
What can a Tirzepatide certificate of analysis establish?
A lot-specific certificate can report the stated identity and analytical results for that lot. It cannot establish receptor activity, sterility, clinical formulation, efficacy, approval, or equivalence to Mounjaro or Zepbound.
References
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: PMID 30473097.
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17). doi:10.1172/jci.insight.140532. PMID: PMID 32730231.
- Sun B, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. PMID: PMID 35333651.
- Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. PMID: PMID 34186022.
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: PMID 34170647.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: PMID 35658024.
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: PMID 38078870.
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PMID: PMID 38912654.
